Cholesterol- and triglycerides-rich remnants
How much will remnant cholesterol lowering reduce ASCVD?
Mie Balling, Denmark
Mie Balling, Denmark
Molecular mechanisms of remnant particle metabolism.
Patrick Rensen, The Netherlands
Patrick Rensen, The Netherlands
Early detection of ASCVD
Polygenic risk scores: Will they be used universally?
Heribert Schunkert, Germany
Heribert Schunkert, Germany
Which imaging technique for whom?
Eugenia Gianos, USA
Eugenia Gianos, USA
EC and SMC atheroheterogeneity in atherosclerosis
Vascular Smooth Muscle Cell Heterogeneity in Disease
Helle Jorgenson, UK
Helle Jorgenson, UK
Impact of Shear Stress and other Microenvironmental Cues on Endothelial Heterogeneity
Elizabeth Jones, Belgium
Elizabeth Jones, Belgium
Genetic dyslipidemias – new insights and novel therapies
Genetic causes of rare dyslipidemia
Mathilde Di Filippo, France
Mathilde Di Filippo, France
Novel strategies in rare lipid disorders
Marcello Arca, Italy
Marcello Arca, Italy
Lipid lowering therapies and metabolic diseases: double edged sword?
Lipid lowering therapies and liver steatosis
Maurizio Averna, Italy
Maurizio Averna, Italy
Statins, bempedoic acid and obicetrapib: how do they affect DM?
Michal Vrablik, Czech Republic
Michal Vrablik, Czech Republic
Lipid-Immune Axis in atherosclerosis
Dyslipidemia-B cell axis in atherosclerosis
Dimitrios Tsiantoulas, Austria
Dimitrios Tsiantoulas, Austria
Modulation of T-cell function and the role of T Cell Plasticity to Drive Atherosclerosis
Dorothee Atzler, Germany
Dorothee Atzler, Germany
Lp(a) in focus: risk stratification, diabetes, and new therapies
The Lp(a) Paradox in Diabetes Mellitus
Samia Mora, USA
Samia Mora, USA
Which patients await new Lp(a) lowering therapies?
Florian Kronenberg, Austria
Florian Kronenberg, Austria
Metabolic regulation of leukocytes in atherosclerosis: Switch maybe Laurent and Fabrizia according to country distribution and gender
Targeting glutamine-glutamate metabolism to treat atherosclerosis
Laurent Yvan-Charvet, France
Laurent Yvan-Charvet, France
Dendritic cells in atherosclerosis development and immunotherapy
David Sancho, Spain
David Sancho, Spain
New insights into CKM and Obesity (Tackling obesity to prevent ASCVD)
GLP-1 signalling in cardiometabolic and renal disease
Anna Solini, Italy
Anna Solini, Italy
Pleiotropic effects of dual and triple incretins on metabolic health
Tomas Lutz, Switzerland
Tomas Lutz, Switzerland
New pathways for lipid and lipoprotein metabolism
Insights in cellular cholesterol sensing
Noam Zelcer, The Netherlands
Noam Zelcer, The Netherlands
Role of HDL in infection and sepsis beyond atherosclerosis
Liam Brunham, Canada
Liam Brunham, Canada
Procoagulatory mechanisms in atherosclerosis
Neutrophils periprandial response in atherosclerosis and CVD
Andrea Baragetti, Italy
Andrea Baragetti, Italy
Macrophage associated coagulation factor in atherosclerosis
Wolfram Ruf, Germany
Wolfram Ruf, Germany
What is the ideal diet to prevent ASCVD?
Time restricted eating and vascular health
Demosthens Panagiotakos, Greece
Demosthens Panagiotakos, Greece
Manipulating gut microbiota to prevent ASCVD. Are we there yet?
Max Nieuwdorp, The Netherlands
Max Nieuwdorp, The Netherlands
